Cancer Immunotherapy in Patients with Preexisting Autoimmune Disorders

Overview

Journal Semin Immunopathol

Publisher Springer

Specialties Allergy & Immunology
Pathology

Date 2016 Oct 13

PMID 27730287

Citations 14

Authors

Marco Donia

Magnus Pedersen

Inge Marie Svane

Affiliations

Soon will be listed here.

Abstract

Patients with preexisting active autoimmune disorders were excluded from clinical trials of immune checkpoint inhibitors. However, patients with autoimmune disorders are diagnosed with cancer at least as frequently as the global population, and clinicians treating patients outside clinical trials have generally been reluctant to offer cancer immunotherapy to this patient group. In this brief article, we review the most recent literature on the efficacy and safety of CTLA-4- and PD-1-blocking antibodies in patients with preexisting autoimmune disorders.

Citing Articles

A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease.

Lopez-Olivo M, Kachira J, Abdel-Wahab N, Pundole X, Aldrich J, Carey P Eur J Cancer. 2024; 207:114148.

PMID: 38834015 PMC: 11331889. DOI: 10.1016/j.ejca.2024.114148.

Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study.

Les I, Perez-Francisco I, Cabero M, Sanchez C, Hidalgo M, Teijeira L Front Pharmacol. 2022; 13:894550.

PMID: 35721217 PMC: 9198493. DOI: 10.3389/fphar.2022.894550.

Byrne M, Lucas M, Pai L, Breeze J, Parsons S Eur J Haematol. 2021; 107(6):650-657.

PMID: 34453348 PMC: 11462459. DOI: 10.1111/ejh.13703.

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach.

Grimaud F, Penaranda G, Stavris C, Retornaz F, Brunel V, Cailleres S Ther Clin Risk Manag. 2021; 17:669-677.

PMID: 34234443 PMC: 8256379. DOI: 10.2147/TCRM.S308194.

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors.

Michailidou D, Khaki A, Morelli M, Diamantopoulos L, Singh N, Grivas P Sci Rep. 2021; 11(1):9029.

PMID: 33907229 PMC: 8079370. DOI: 10.1038/s41598-021-88307-3.

References

Dugowson C, Koepsell T, Voigt L, Bley L, Nelson J, Daling J . Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987-1989. Arthritis Rheum. 1991; 34(12):1502-7. DOI: 10.1002/art.1780341205. View

Walsh S, Rau L . Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States. Am J Public Health. 2000; 90(9):1463-6. PMC: 1447637. DOI: 10.2105/ajph.90.9.1463. View

Engels E, Pfeiffer R, Fraumeni Jr J, Kasiske B, Israni A, Snyder J . Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306(17):1891-901. PMC: 3310893. DOI: 10.1001/jama.2011.1592. View

Johnson D, Sullivan R, Ott P, Carlino M, Khushalani N, Ye F . Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2015; 2(2):234-40. DOI: 10.1001/jamaoncol.2015.4368. View

Dunn G, Koebel C, Schreiber R . Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006; 6(11):836-48. DOI: 10.1038/nri1961. View

Kingwell E, Marriott J, Jette N, Pringsheim T, Makhani N, Morrow S . Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013; 13:128. PMC: 3856596. DOI: 10.1186/1471-2377-13-128. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G . The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann Oncol. 2016; 27(6):1174-1177. DOI: 10.1093/annonc/mdw056. View

Grivennikov S, Greten F, Karin M . Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. PMC: 2866629. DOI: 10.1016/j.cell.2010.01.025. View

10.

Weber J, Kahler K, Hauschild A . Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30(21):2691-7. DOI: 10.1200/JCO.2012.41.6750. View

11.

Borch T, Donia M, Andersen M, Svane I . Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discov Today. 2015; 20(9):1127-34. DOI: 10.1016/j.drudis.2015.07.003. View

12.

Raaschou P, Simard J, Neovius M, Askling J . Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum. 2011; 63(7):1812-22. DOI: 10.1002/art.30247. View

13.

Horvat T, Adel N, Dang T, Momtaz P, Postow M, Callahan M . Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015; 33(28):3193-8. PMC: 5087335. DOI: 10.1200/JCO.2015.60.8448. View

14.

Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D . Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014; 6(254):254ra128. DOI: 10.1126/scitranslmed.3008918. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Fairweather D, Rose N . Women and autoimmune diseases. Emerg Infect Dis. 2004; 10(11):2005-11. PMC: 3328995. DOI: 10.3201/eid1011.040367. View

17.

Raaschou P, Frisell T, Askling J . TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014; 74(12):2137-43. DOI: 10.1136/annrheumdis-2014-205745. View

18.

Beck K, Dong J, Geskin L, Beltrani V, Phelps R, Carvajal R . Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. J Immunother Cancer. 2016; 4:20. PMC: 4835882. DOI: 10.1186/s40425-016-0123-3. View

19.

Margolin K, Ernstoff M, Hamid O, Lawrence D, McDermott D, Puzanov I . Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13(5):459-65. DOI: 10.1016/S1470-2045(12)70090-6. View

20.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View